BDTX: Silevertinib delivers best-in-class CNS efficacy and broad mutation coverage in NSCLC and GBM

Silevertinib shows strong efficacy and CNS activity in NSCLC with non-classical EGFR mutations, outperforming competitors in both mutation coverage and brain penetrance. Regulatory discussions are underway for a pivotal trial, with a phase II GBM study also progressing and financial runway secured…